てんかん治療薬市場：製品タイプ別、流通チャネル別-2025-2030年の世界予測

てんかん治療薬市場は、2023年に45億5,000万米ドルと評価され、2024年には48億7,000万米ドルに達すると予測され、CAGR 7.09％で成長し、2030年には73億5,000万米ドルに達すると予測されています。

てんかん治療薬市場には、てんかん（反復性発作を特徴とする神経疾患）の管理および治療用に設計された多様な医薬品が含まれます。これらの薬剤の必要性は、てんかん患者の発作を抑制し、副作用を最小限に抑え、生活の質を向上させる必要性から生じる。これらの治療薬は、主に病院や診療所のヘルスケアプロバイダーや患者自身によって使用され、治療レジメンの不可欠な部分を形成しています。薬理学の進歩により、最終用途の範囲が広がり、様々な個人のニーズに対応するジェネリック医薬品と特殊医薬品の両方が含まれるようになった。市場開拓に影響を与える主な要因としては、てんかんの有病率の増加、神経疾患に対する意識の高まり、薬剤開発と製剤化の進歩などが挙げられます。さらに、個別化医療や生物製剤の革新は大きな成長機会をもたらします。特筆すべき機会の1つは、従来の治療に抵抗性を示す特定のてんかんをターゲットとした、有効性の向上と副作用の軽減を実現した薬剤の開発です。しかし、高い薬剤開発コスト、厳しい規制プロセス、潜在的な副作用などの課題が市場成長の妨げとなっています。さらに、特許切れはジェネリック医薬品による市場飽和のリスクをもたらし、収益性に影響を及ぼします。こうした制約に対抗するためには、新たな治療メカニズムの研究に注力し、ゲノム解析やAIを活用した創薬など、個別化治療のための技術を活用することが非常に有利となる可能性があります。競争が激しく、規制が厳しいという市場の性質を考慮すれば、研究機関との戦略的提携や、薬効に関する実世界のエビデンスを活用することで、開発期間を短縮できる可能性があります。また、医療費が増加し、アンメット・メディカル・ニーズが高まっている新興市場への投資も、大きな成長軌道をもたらす可能性があります。このように、イノベーションと研究の最良の領域は、アンメットニーズに対応し、患者のアドヒアランスを改善し、進化する医療政策に合致する治療ソリューションを開発することであり、それによって市場の持続的成長とリーダーシップを確保することです。

市場力学：急速に進化するてんかん治療薬市場の主要市場インサイトを公開

てんかん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • てんかん患者の増加
  • 神経疾患、出産関連傷害、交通傷害の発生率の上昇
  • 政府からの投資と支援の増加
• 市場抑制要因
  • インフラの不足とてんかん治療の不足
• 市場機会
  • 規制当局による抗けいれん薬の承認増加
  • 共同研究や製品上市活動の浸透
• 市場の課題
  • 薬剤に伴う副作用

ポーターの5つの力：てんかん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：てんかん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、てんかん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析てんかん治療薬市場における競合情勢の把握

てんかん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスてんかん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、てんかん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨てんかん治療薬市場における成功への道筋を描く

てんかん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • てんかんの罹患率の増加
    • 神経疾患、出産関連傷害、交通事故の発生率の上昇
    • 政府からの投資と支援の増加
  • 抑制要因
    • てんかんのインフラ不足と治療の不足
  • 機会
    • 規制当局による抗けいれん薬の承認増加
    • コラボレーションと製品発売活動の浸透
  • 課題
    • 薬に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 てんかん治療薬市場：製品タイプ別

• 第一世代の医薬品
  • エトスクシミド
  • オキシカルバゼピン
  • フェニトイン
• 第二世代の医薬品
  • フェルバメート
  • ラモトリギン
  • トピラマート
• 第三世代の医薬品
  • エスリカルバゼピン酢酸塩
  • ラコサミド
  • ラルフィナミド

第7章 てんかん治療薬市場：流通チャネル別

• 病院薬局
• 薬局

第8章 南北アメリカのてんかん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のてんかん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのてんかん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Densa Pharmaceuticals Pvt. Ltd.
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Micro Labs Ltd.
• Novartis International AG
• Pfizer Inc.
• Psychotropics India Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Sunovion Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
• FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. EPILEPSY DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. EPILEPSY DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL EPILEPSY DRUG MARKET SIZE, BY OXCARBAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FELBAMATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ESLICARBAZEPINE ACETATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LACOSAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL EPILEPSY DRUG MARKET SIZE, BY RALFINAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. POLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. QATAR EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 236. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Epilepsy Drug Market was valued at USD 4.55 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 7.09%, to USD 7.35 billion by 2030.

The epilepsy drug market encompasses a diverse range of medications designed for the management and treatment of epilepsy, a neurological disorder characterized by recurrent seizures. The necessity for these drugs arises from the need to control seizures, minimize side effects, and improve quality of life for epilepsy patients. These medications are primarily utilized by healthcare providers in hospitals, clinics, and by patients themselves, forming an integral part of treatment regimens. Advances in pharmacology have broadened the end-use scope to encompass both generic and specialty drugs catering to various individual needs. Key factors influencing market growth include increased prevalence of epilepsy, heightened awareness about neurological disorders, and advancements in drug development and formulation. Additionally, innovation in personalized medicine and biologics presents significant growth opportunities. One notable opportunity is the development of drugs with improved efficacy and reduced side effects, targeting specific types of epilepsy that are resistant to conventional treatments. However, challenges such as high drug development costs, stringent regulatory processes, and potential side effects hinder market growth. Moreover, patent expirations pose risks of market saturation with generics, impacting profitability. To counter these limitations, focusing on research for new treatment mechanisms and leveraging technology for personalized treatments, such as genomics and AI-driven drug discovery, could be highly advantageous. Given the nature of the market being highly competitive and heavily regulated, strategic alliances with research institutions and leveraging real-world evidence for drug efficacy could accelerate development timelines. Investments in emerging markets with rising healthcare expenditures and unmet medical needs could also provide substantial growth trajectories. Thus, the best areas of innovation and research involve developing therapeutic solutions that address unmet needs, improve patient adherence, and align with evolving healthcare policies, thereby ensuring sustained market growth and leadership.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Epilepsy Drug Market

The Epilepsy Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalences of epilepsy
  • Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
  • Rising investment and support from the government
• Market Restraints
  • Lack of infrastructure and scarcity of treatment for epilepsy
• Market Opportunities
  • Rising drug approvals of anticonvulsant drugs from regulatory bodies
  • Penetration of collaboration and product launch activities
• Market Challenges
  • Side effects associated with the drugs

Porter's Five Forces: A Strategic Tool for Navigating the Epilepsy Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Epilepsy Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Epilepsy Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Epilepsy Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Epilepsy Drug Market

A detailed market share analysis in the Epilepsy Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Epilepsy Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Epilepsy Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Epilepsy Drug Market

A strategic analysis of the Epilepsy Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Epilepsy Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Densa Pharmaceuticals Pvt. Ltd., Eisai Co., Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Micro Labs Ltd., Novartis International AG, Pfizer Inc., Psychotropics India Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Epilepsy Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The First-Generation Drugs is further studied across Ethosuximide, Oxcarbazepine, and Phenytoin. The Second-Generation Drugs is further studied across Felbamate, Lamotrigine, and Topiramate. The Third-Generation Drugs is further studied across Eslicarbazepine Acetate, Lacosamide, and Ralfinamide.
• Based on Distribution Channel, market is studied across Hospital Pharmacy and Pharmacy Stores.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalences of epilepsy
    • 5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
    • 5.1.1.3. Rising investment and support from the government
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • 5.1.3.2. Penetration of collaboration and product launch activities
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Epilepsy Drug Market, by Product Type

• 6.1. Introduction
• 6.2. First-Generation Drugs
  • 6.2.1. Ethosuximide
  • 6.2.2. Oxcarbazepine
  • 6.2.3. Phenytoin
• 6.3. Second-Generation Drugs
  • 6.3.1. Felbamate
  • 6.3.2. Lamotrigine
  • 6.3.3. Topiramate
• 6.4. Third-Generation Drugs
  • 6.4.1. Eslicarbazepine Acetate
  • 6.4.2. Lacosamide
  • 6.4.3. Ralfinamide

7. Epilepsy Drug Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Pharmacy Stores

8. Americas Epilepsy Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Epilepsy Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Epilepsy Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Densa Pharmaceuticals Pvt. Ltd.
• 3. Eisai Co., Ltd.
• 4. GlaxoSmithKline PLC
• 5. Johnson & Johnson Services, Inc.
• 6. Micro Labs Ltd.
• 7. Novartis International AG
• 8. Pfizer Inc.
• 9. Psychotropics India Ltd.
• 10. Sanofi S.A.
• 11. Sun Pharmaceutical Industries Ltd.
• 12. Sunovion Pharmaceuticals, Inc.
• 13. Teva Pharmaceutical Industries Ltd.
• 14. Torrent Pharmaceuticals Ltd.
• 15. UCB S.A.